Scholar Rock Holding (SRRK) Non Operating Income (2017 - 2026)
Scholar Rock Holding (SRRK) posted quarterly Non Operating Income of -$3.5 million for Q1 2026, down 247.61% year-over-year from $2.4 million in Q1 2025, and down 475.3% quarter-over-quarter from $931000.0 in Q4 2025.
Scholar Rock Holding (SRRK) Non Operating Income (2017 - 2026) Analysis & Trends
Scholar Rock Holding's Non Operating Income history runs 10 years deep, the most recent figure standing at -$3.5 million for Q1 2026.
- In Q1 2026, Non Operating Income fell 247.61% year-over-year to -$3.5 million; the TTM figure through Mar 2026 stood at $845000.0 (down 87.12% YoY), while the FY2025 annual figure was $6.7 million, up 16.42% from the prior year.
- Non Operating Income for Q1 2026 stood at -$3.5 million, down from $931000.0 in the prior quarter.
- The five-year high for Non Operating Income was $2.9 million in Q4 2024, with the low at -$3.5 million in Q1 2026.
- The 5-year median for Non Operating Income is $1.2 million (2023), against an average of $843882.4.
- The sharpest annual moves came in 2025 and 2026: Non Operating Income surged 341.86% in 2025, then slumped 247.61% in 2026.
- Scholar Rock Holding's Non Operating Income stood at $1.2 million in 2022, then soared by 62.49% to $1.9 million in 2023, then jumped by 52.31% to $2.9 million in 2024, then plunged by 67.93% to $931000.0 in 2025, then tumbled by 475.3% to -$3.5 million in 2026.
- Business Quant data shows SRRK's Non Operating Income at -$3.5 million in Q1 2026, $931000.0 in Q4 2025, and $1.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -139.24 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 12.40 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -51.63 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -53.64 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Scholar Rock Holding | 6.39 Bn | 6.39 Bn | - | -995,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -995,000.00 |
| Mar 31, 2026 | -3.49 Mn |
| Dec 31, 2025 | 931,000.00 |
| Sep 30, 2025 | 1.33 Mn |
| Jun 30, 2025 | 2.08 Mn |
| Mar 31, 2025 | 2.37 Mn |
| Dec 31, 2024 | 2.90 Mn |
| Sep 30, 2024 | 301,000.00 |
| Jun 30, 2024 | 990,000.00 |
| Mar 31, 2024 | 1.57 Mn |
| Dec 31, 2023 | 1.91 Mn |
| Sep 30, 2023 | 1.31 Mn |
| Jun 30, 2023 | 1.16 Mn |
| Mar 31, 2023 | 1.13 Mn |
| Dec 31, 2022 | 1.17 Mn |
| Sep 30, 2022 | 565,000.00 |
| Jun 30, 2022 | -853,000.00 |
| Mar 31, 2022 | -1.02 Mn |
| Dec 31, 2021 | -550,000.00 |
| Sep 30, 2021 | -430,000.00 |